Wednesday, December 31, 2025 12/31/2025

Advancing rare disease discovery through technological and methodological approaches using an intuitive platform, seqr

Award Number: R01HG013986
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/08/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Advancing rare disease discovery through technological and methodological approaches using an intuitive platform, seqr - PROJECT SUMMARY / ABSTRACT Over half of all rare disease families remain undiagnosed following exome and genome sequencing analysis. Remarkable developments in genomic technologies, analytical tools, and innovative data sharing are advancing Mendelian gene discovery. However, the benefits of these novel advances will only become realized if they are integrated into widely accessible platforms for genomic analysis. The Broad Institute Center for Mendelian Genomics has supported the deployment and ongoing development of the seqr genomic analysis platform, which is freely available to the community either on the AnVIL platform or as an open-source tool that can be installed locally. This proposal seeks to advance the discovery rate for rare disease through ongoing development of the seqr platform, incorporating and evaluating the impact of three novel advances: 1) innovative data sharing through variant level matching by connecting seqr to a growing federated platform of rare disease and population genomic data with associated phenotype; 2) deployment of automated analytical tools on previously examined and unsolved cases to identify variation that is newly implicated as pathogenic in genes with known disease associations or in genes that are newly implicated in disease; and 3) incorporation of novel technologies such as long read DNA and RNA sequencing data that can be easily analyzed in a genome-wide manner. We will study the impact of these novel advances by analyzing the diagnostic yield of each approach. As seqr is freely available and open source, our proposal democratizes the process of genetic discovery, empowering researchers and clinicians to resolve diagnostic variants, and accelerate the rate of diagnosis for the global population of individuals with rare genetic disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Human Genome Research	000	1	12/11/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $3,349,527 )
2025	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Human Genome Research	000	1	9/8/2025	NEW	$3,349,527
														Subtotal = $3,349,527

Grand Total All Awards = $3,349,527

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing rare disease discovery through technological and methodological approaches using an intuitive platform, seqr

Award Number: R01HG013986

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/08/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer